Precision Business Insights
Portfolio

 

Research Reports

Oral Solid Dosage Pharmaceutical Formulation Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Oral Solid Dosage Pharmaceutical Formulation Market

 

By Product Type (Tablets, Lozenges, Capsules), By Drug Release Mechanism (Sustained Release, Extended Release, Instant Release, Chewable Tablets, Effervescent Tablets, Enteric Release), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

 

Global oral solid dosage pharmaceutical formulation market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

 

Market Outline: Oral Solid Dosage Pharmaceutical Formulation Market

Oral solid dosage pharmaceutical formulation are most widely used dosage forms. They are easy to manufacture and transport due to its increased chemical and physical stability. The Oral solid dosage formulations are cost effective when compared with the other kind of dosage forms. These can be formulated in various flavors in order to mask the unpleasant taste of the formulation and increase the patient compliance. The technological advancements are enabling the manufacturers to formulate new drugs such as sustained release dosage forms which minimize the frequent administration of the drug.

 

Market Dynamics: Oral Solid Dosage Pharmaceutical Formulation Market

Market players are majorly focused on oral solid dosage forms due to convenience and safe way of administration. Increased sedentary and fast paced lifestyle is leading to adopt lifestyle related diseases such as obesity, diabetes. The manufacturers are targeting the population in developing countries in order to enhance the market. A significant boost is observed in the Asia Pacific region owing to increased population. Moreover, the generic manufacturers are playing a major role in the growth of the oral solid dosage pharmaceutical formulation market by introducing generic drugs in the local market. However, the high regulatory requirement is expected to hamper the market.

 

Market Scope: Oral Solid Dosage Pharmaceutical Formulation Market

Oral solid dosage pharmaceutical formulation market is segmented based on the type, drug release mechanism, and distribution channel

Based on the type, the market is segmented into the following:

  • Tablets
  • Lozenges
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules

Based on the Drug Release Mechanism, the market is segmented into the following:

  • Sustained Release
  • Extended Release
  • Instant Release
  • Chewable Tablets
  • Effervescent Tablets
  • Enteric Release

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

 

Regional Analysis:  Oral Solid Dosage Pharmaceutical Formulation Market

Geographically, global oral solid dosage pharmaceutical formulation market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominates the oral solid dosage pharmaceutical formulation market and expected to grow at significant CAGR over the forecasted period. North America being more lucrative showing the higher expectancy of market growth. Asia Pacific oral solid dosage pharmaceutical formulation market is expected to show higher growth rate. The emerging countries such as India and China are showing a significant growth due to the entry of local market players which formulate the generic drugs.

 

Competition Assessment: Oral Solid Dosage Pharmaceutical Formulation Market

Some of the players in the global oral solid dosage pharmaceutical formulation market include:

  • AstraZeneca Plc. (UK)
  • Bristol-Myers Squibb Company (U.S)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S)
  • AbbVie Inc. (U.S)
  • Boehringer Ingelheim GmbH (Germany)
  • Johnson & Johnson (U.S)
  • Merck & Co. Inc. (U.S)
  • Gilead Sciences (U.S)

 

Notable Market Developments: Oral Solid Dosage Pharmaceutical Formulation Market

  • In Feburary 2018, Colorcon, Inc., has introduced the Opadry EZ, Easy Swallow Film Coating System, a new product aimed at addressing the difficulty faced by many patients in swallowing oral solid dosage forms.

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • AstraZeneca Plc. (UK)
  • Bristol-Myers Squibb Company (U.S)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S)
  • AbbVie Inc. (U.S)
  • Boehringer Ingelheim GmbH (Germany)
  • Johnson & Johnson (U.S)
  • Merck & Co. Inc. (U.S)
  • Gilead Sciences (U.S)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Select License Type

Databank $ 3,000.00
spinner
Single User $ 4,400.00
spinner
Multiple User $ 6,600.00
spinner
Corporate User $ 8,900.00
spinner
buy now spinner
FacebookTwitterLinkedinEmail

Our Clients

Testimonials

Contact SalesTOLL FREE: +1-866-598-1553